Rosacea /
Saved in:
| Imprint: | Cham, Switzerland : Springer, [2020] |
|---|---|
| Description: | 1 online resource. |
| Language: | English |
| Series: | Updates in clinical dermatology Updates in clinical dermatology. |
| Subject: | |
| Format: | E-Resource Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/12607903 |
MARC
| LEADER | 00000cam a2200000Ii 4500 | ||
|---|---|---|---|
| 001 | 12607903 | ||
| 005 | 20210813213023.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 201002s2020 sz a ob 001 0 eng d | ||
| 015 | |a GBC0H5316 |2 bnb | ||
| 016 | 7 | |a 019967384 |2 Uk | |
| 019 | |a 1202453892 |a 1202468725 |a 1203215974 | ||
| 020 | |a 3030520978 |q electronic book | ||
| 020 | |a 9783030520977 |q (electronic bk.) | ||
| 020 | |z 303052096X | ||
| 020 | |z 9783030520960 | ||
| 024 | 7 | |a 10.1007/978-3-030-52097-7 |2 doi | |
| 035 | |a (OCoLC)1198557259 |z (OCoLC)1202453892 |z (OCoLC)1202468725 |z (OCoLC)1203215974 | ||
| 035 | 9 | |a (OCLCCM-CC)1198557259 | |
| 037 | |a com.springer.onix.9783030520977 |b Springer Nature | ||
| 040 | |a YDX |b eng |e rda |c YDX |d YDXIT |d EBLCP |d EQF |d UKMGB |d UKAHL |d OCLCF |d GW5XE |d OCLCO |d N$T |d OCLCO | ||
| 049 | |a MAIN | ||
| 050 | 4 | |a RL325 |b .R67 2020 | |
| 245 | 0 | 0 | |a Rosacea / |c John Havens Cary, Howard I. Maibach, editors. |
| 264 | 1 | |a Cham, Switzerland : |b Springer, |c [2020] | |
| 300 | |a 1 online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Updates in clinical dermatology | |
| 504 | |a Includes bibliographical references and index. | ||
| 588 | |a Description based on online resource; title from digital title page (viewed on November 02, 2020). | ||
| 505 | 0 | |a Intro -- Preface -- Contents -- Contributors -- 1: Introduction to Clinical Rosacea -- Rosacea Is a Syndrome and Not a Pathogenically Defined Disease -- History of Classification of Rosacea: Distinction from Acne and Recognition of Phenotypic Subtypes -- The Four Classic Phenotypic Subtypes of Rosacea Have Important Utilities -- The Flawed Proposal to Eliminate the Classic Phenotypic Subtypes -- The Classic Phenotypic Subtypes Are Useful and Will Persist -- Incidence -- History -- History of Present Illness -- Past Medical History -- Medication History -- Family History -- Social History | |
| 505 | 8 | |a Review of Systems -- Physical Exam -- Differential Diagnoses -- Histology -- References -- 2: Pathophysiology of Rosacea -- Introduction -- Current Concepts of the Pathophysiology -- Genes in Rosacea -- Innate Immunity and Adaptive Immunity -- Neuroimmune and Neurovascular Dysregulation -- Novel Insights and Promising Targets -- Future Studies -- Conclusion -- References -- 3: Genetics of Rosacea -- Background -- Epidemiology -- Familial Inheritance Studies -- Twin Concordance Studies -- Gene Association Case-Control Studies -- Molecular and Functional Data -- Endoplasmic Reticulum (ER) Stress | |
| 505 | 8 | |a Toll-Like Receptor (TLR)-2 -- Antimicrobial Peptides -- Transient Receptor Potential Vanilloid 1 (TRPV1) -- Neurovascular Factors -- Mast Cells -- IL-17 -- TSLP -- Associations with Comorbidities -- Conclusion and Future Directions -- References -- 4: Evidence-Based Management -- Introduction -- Environmental Modification -- Topical Therapies -- Metronidazole -- Azelaic Acid -- Sodium Sulfacetamide-Sulfur -- Calcineurin Inhibitors -- Crotamiton, Ivermectin, and Permethrin -- Clindamycin -- Retinoids -- Systemic Therapies -- Doxycycline and Minocycline -- Macrolides -- Antihypertensives | |
| 505 | 8 | |a Isotretinoin -- Conclusion -- References -- 5: Difference in Vasoconstrictors: Oxymetazoline Versus Brimonidine -- Introduction -- Vascular Anatomy -- Brimonidine -- Pharmacodynamics and Pharmacokinetics -- Administration and Interactions -- Indication and Clinical Management -- Efficacy -- Adverse Effects -- Oxymetazoline -- Pharmacodynamics and Pharmacokinetics -- Administration and Interactions -- Indication and Clinical Management -- Efficacy -- Adverse Effects -- Oxymetazoline Versus Brimonidine -- Conclusion -- References -- 6: Treatment of Ocular Rosacea -- Introduction | |
| 505 | 8 | |a Conservative Therapy -- Topical Medical Therapy -- Systemic Therapy -- Procedural and Surgical Therapy -- Future Directions -- Conclusion -- References -- 7: Physical Modalities for the Treatment of Rosacea -- Introduction -- Light and Laser Applications for Vascular Lesions -- Pulsed Dye Laser (PDL) -- KTP Laser -- Long-Pulsed Nd:YAG Laser -- Intense Pulse Light (IPL) -- Summary: Therapy of Vascular Lesions -- Physical Therapeutic Options in the Treatment of Phymatous Rosacea Manifestations -- Dermashaving (Scalpel) -- Dermabrasion -- Electrosurgery (Fig. 7.1a-c) -- Laser Surgery (Fig. 7.2a, b) | |
| 520 | |a Of Therapeutic Options in Phymatous Lesions of Rosacea. | ||
| 650 | 0 | |a Rosacea. |0 http://id.loc.gov/authorities/subjects/sh85115399 | |
| 650 | 7 | |a Rosacea. |2 fast |0 (OCoLC)fst01100462 | |
| 655 | 4 | |a Electronic books. | |
| 700 | 1 | |a Cary, John Havens, |e editor. | |
| 700 | 1 | |a Maibach, Howard I., |e editor. | |
| 776 | 0 | 8 | |i Print version: |z 303052096X |z 9783030520960 |w (OCoLC)1156341094 |
| 830 | 0 | |a Updates in clinical dermatology. |0 http://id.loc.gov/authorities/names/n2018187819 | |
| 903 | |a HeVa | ||
| 929 | |a oclccm | ||
| 999 | f | f | |i 01e695c0-43bc-5b37-a112-727c3684dc34 |s ae48358d-98d8-54fa-92f3-0a1f0fd1f0b9 |
| 928 | |t Library of Congress classification |a RL325 .R67 2020 |l Online |c UC-FullText |u https://link.springer.com/10.1007/978-3-030-52097-7 |z Springer Nature |g ebooks |i 12623511 | ||